학술논문
Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial
Document Type
Article
Author
Source
In: The Lancet Oncology . (The Lancet Oncology, October 2019, 20(10):1409-1419)
Subject
Language
English
ISSN
14745488
14702045
14702045